Generic placeholder image

Current Radiopharmaceuticals


ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Targeted Alpha Therapy with 213Bi

Author(s): Alfred Morgenstern, Frank Bruchertseifer and Christos Apostolidis

Volume 4, Issue 4, 2011

Page: [295 - 305] Pages: 11

DOI: 10.2174/1874471011104040295

Price: $65


The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, preclinical studies, clinical application, Alpha emitting radionuclides, RADIONUCLIDE GENERATORS, radiolabeled peptide, SPECT

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy